- Home
- QNCX vs NSPR Comparison
QNCX vs NSPR Comparison
Compare QNCX & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- NSPR
- Stock Information
- Founded
- QNCX 2012
- NSPR 2005
- Country
- QNCX United States
- NSPR United States
- Employees
- QNCX N/A
- NSPR N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- NSPR Medical/Dental Instruments
- Sector
- QNCX Health Care
- NSPR Health Care
- Exchange
- QNCX Nasdaq
- NSPR Nasdaq
- Market Cap
- QNCX 88.6M
- NSPR 99.7M
- IPO Year
- QNCX 2019
- NSPR N/A
- Fundamental
- Price
- QNCX $1.60
- NSPR $2.13
- Analyst Decision
- QNCX Strong Buy
- NSPR Strong Buy
- Analyst Count
- QNCX 6
- NSPR 2
- Target Price
- QNCX $8.00
- NSPR $4.50
- AVG Volume (30 Days)
- QNCX 271.4K
- NSPR 70.2K
- Earning Date
- QNCX 11-12-2025
- NSPR 11-04-2025
- Dividend Yield
- QNCX N/A
- NSPR N/A
- EPS Growth
- QNCX N/A
- NSPR N/A
- EPS
- QNCX N/A
- NSPR N/A
- Revenue
- QNCX N/A
- NSPR $7,779,000.00
- Revenue This Year
- QNCX N/A
- NSPR $7.48
- Revenue Next Year
- QNCX N/A
- NSPR $104.39
- P/E Ratio
- QNCX N/A
- NSPR N/A
- Revenue Growth
- QNCX N/A
- NSPR 14.04
- 52 Week Low
- QNCX $0.72
- NSPR $1.99
- 52 Week High
- QNCX $2.45
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- QNCX 37.36
- NSPR 30.59
- Support Level
- QNCX $1.76
- NSPR $2.10
- Resistance Level
- QNCX $1.88
- NSPR $2.41
- Average True Range (ATR)
- QNCX 0.10
- NSPR 0.11
- MACD
- QNCX -0.03
- NSPR -0.01
- Stochastic Oscillator
- QNCX 9.28
- NSPR 20.27
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.